Ettore Biagi, Senior Medical Director at AstraZeneca, shared a post on LinkedIn:
“Outstanding clinical benefit in hard-to-treat pediatric ALL. Chemo-immunotherapy is a revolutionary approach over multiple tumor types.
Recently published in JCO. Free download available.
J Clin Oncol, 2026 vol. 44(5) pp. 370-374
“Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics”
Vieira Martins, M et al
KMT2A-rearranged infant ALL (KMT2A-r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to standard chemotherapy for infants with KMT2A-r ALL improved short-term outcomes.
Here, the authors present long-term results, toxicity, and pharmacokinetics of blinatumomab.
Thirty infants received Interfant-06 protocol chemotherapy with one additional postinduction blinatumomab course. Disease-free survival (DFS) and overall survival (OS) were compared with a historical Interfant-06-selected cohort without blinatumomab. The median follow-up was 4.2 years (range, 3.2-6.0).
Blinatumomab significantly improved outcomes compared with controls, with a 4-year DFS of 83.3% versus 44.0% and a 4-year OS of 93.3% versus 60.2%. No infection-related fatality occurred postinduction, in contrast to 4% in Interfant-06.
Adding blinatumomab to standard treatment for infants with KMT2A-r ALL resulted in sustained improvement in outcome.”
Title: Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
Author: Paige Britt.
Other articles on OncoDaily.